This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Biotie Therapies Corp.
Drug Names(s): Naltrexone Depot
Description: Naltrexone Depot is an extended-release injectable form of naltrexone, a medication that binds competitively at the opiate receptor sites in the brain. The precise mechanism of its action in the treatment of alcoholism is unknown.
Deal Structure: In January 2007, elbion announced it has acquired a number of product candidates from DrugAbuse Sciences including Naltrexone Depot. The acquisition of the DrugAbuse Sciences candidates was made in return for a financial consideration comprising elbion shares. Full financial terms were not disclosed.
In October 2008, Biotie entered into an agreement to acquire elbion GmbH. The deal closed in November, 2008.
Acorda and Biotie
In January 2015, Acorda Therapeutics and Biotie Therapies have entered into a combination agreement (Combination Agreement) whereby Acorda, either directly or through a wholly-owned subsidiary (jointly the Offeror), will make a public tender offer in Finland and in the United States to purchase all of the issued and outstanding shares, American Depositary Shares (ADSs), stock options, share units and warrants in Biotie that are not owned by Biotie or any of its subsidiaries (the Tender Offer).
The price offered for each share...See full deal structure in Biomedtracker
Naltrexone Depot News
Pink Sheet US FDA, Advisory Committees Rarely Disagree
Additional information available to subscribers only: